Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Cotinga Pharmaceuticals Inc COTQF

Cotinga Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company's lead clinical candidate, COTI-2, is an oral small molecule targeting p53, a tumor suppressor gene that is mutated in over 50% of all cancers, and the company's second clinical candidate, COTI-219, is a novel oral small molecule compound targeting the mutant forms of KRAS with such mutations occurring in up... see more

GREY:COTQF - Post Discussion

View:
Post by Cotitwo on Sep 10, 2018 11:25am

M D Anderson

I have not given up Hope with this company. We need a break. and hopefully it will come from M D Anderson. We have been waiting for them to start the Combination study with Coti 2 and Cisplatin for about 5 weeks now
I think once it starts we should see some very positive results and there are eyes waiting for results
All the clinical studies which you can find on there web site showed positive results in all cases
There is one diagram showing four of 9 species literally cancer free after 2 months. So its a clinical study you say
Well what they did is took FDA approved cancer drugs that people take every day of there lives and compared it to Coti2 and got similar results. When they combined it with Coti2 in every instance they approved the results dramatically 
I spoke with the former CSO of the company who is still very positive on COT and he feels that a dosage of 0.75 milligrams could be the dosage where it could be beneficial to the patients
Were starting at 0.5 mgs and go up from there so we could see results rather quickly
Each cohort starts at 0.5 mgs for 3 weeks along with a dosage of Cisplatin. After 3 weeks they have testing done and continue on the same dose
Once 3 cohorts complete there 3 weeks  successfuly they start the next 3 cohorts at a higher dosage [ i heard 1mg ] and go from there.
So come on MDACC lets get this study going
im open to questions and criticism
Comment by monkeydancer on Sep 10, 2018 12:47pm
Thank you for your thoughts. The art of promotion and managing perception is lost on this company. The silence is being interpreted as failing by the market and hammering long time shareholders.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities